Posts Tagged ‘cancer’

Nanotubes, nanofibers tested as anticancer delivery depots

Thursday, July 29th, 2010

Despite the efforts of some anti-nanotech groups to paint carbon nanotubes as hazardous to human health, the reality is that they increasingly show promise as drug-delivery devices. The latest proof of that comes from researchers in Germany who showed that tubular nanomaterials, such as carbon nanotubes and carbon nanofibers, are promising delivery agents for anticancer drugs.

The researchers used the materials as drug depots to deliver the anti-cancer drug carboplatin in vitro. The result: No significant intrinsic toxicity of unloaded materials was found, confirming their biocompatibility. And carboplatin that was delivered by carbon nanotubes exhibited higher anticancer activity than free carboplatin.

It’s not anything conclusive. But that’s the way science works. One study builds upon another. It sounds like a better method of determining carbon nanotube toxicity than the anti-nano groups’ method of declaring all nanomaterials to be toxic.

Read the full story here.

Onyx Pharma calls myeloma data “impressive”

Monday, July 26th, 2010

LOS ANGELES, July 26 (Reuters) – Nearly a quarter of trial patients with multiple myeloma that had stopped reacting to current drugs responded to an experimental cancer drug, carfilzomib, being developed by Onyx Pharmaceuticals Inc.

Onyx said it plans to use the single-arm study results, released on Monday, as the basis for a new drug application (NDA) at the U.S. Food and Drug Administration before the end of the year.

“We think these are very impressive data,” Onyx Chief Executive Officer Tony Coles told Reuters. “We expect to file an NDA by the end of this year.”

He said Onyx will seek an accelerated six-month review by the FDA based on the unmet need of the intravenous drug’s target population, as well as its efficacy and tolerability.

The mid-stage trial involved 266 severely ill multiple myeloma patients whose cancer had worsened after an average of five prior treatment regimens.

The study found that 24 percent of the patients responded to carfilzomib for a median duration of 7.4 months.

Coles said Onyx had expected a response rate for such heavily-pretreated patients in the mid-teens with a response duration of four to six months.

A study by the International Myeloma Working Group found that myeloma patients as sick as those enrolled in the Onyx study can expect to respond to therapy 11 percent of the time.

The company did not release full details of the trial, including side effects, but said the drug was well-tolerated and there were no new or unexpected toxicities.

Coles said about 50,000 American have multiple myeloma, a cancer the develops in cells of the bone marrow, and about 20,000 new cases are diagnosed each year. Around 20 percent of patients are considered “relapsed and refractory,” meaning that their cancer no longer responds to standard drugs including Takeda Pharmaceutical Co’s Velcade.

Onyx is also studying carfilozimb, a proteasome inhibitor, in patients with earlier-stage myeloma.

Onyx acquired carfilzomib developer Proteolix Inc last year for an upfront cash payment of $276 million and potential milestone payments of up to $535 million

Read the full story here at Reuters.

Pfizer stops two more trials of pain drug tanezumab

Thursday, July 22nd, 2010

Pfizer has been forced to halt two more trials of tanezumab, an experimental biologic for pain. The FDA requested that Pfizer suspend two late-stage trials of the drug in patients with chronic low back pain and painful diabetic peripheral neuropathy. The move comes after the drug giant suspended another trial of the biologic in June. In that study, patients taking the therapy for osteoarthritis saw their condition worsen to the point they required joint replacement surgery.

The FDA told Pfizer to halt the trials following reports of further adverse events in patients enrolled in the suspended osteoarthritis study. The agency was concerned that those events would also crop up in Pfizer’s other studies of tanezumab. The developer says it will continue to work with the FDA to determine how best to proceed with the rest of its tanezumab studies.

Tanezumab is an infused biologic which is designed to block pain by inhibiting nerve growth factor. If approved, it would be the first biotech therapy for pain. According to Pfizer’s statement, investigation of the compound is ongoing in some areas of high unmet medical need, including cancer pain.

- take a look at Pfizer’s announcement
- read here for more

Amgen’s Prolia wins priority review for cancer use

Tuesday, July 20th, 2010

Amgen’s great new hope–the bone drug Prolia–won priority review at the FDA for a new, potentially lucrative cancer indication. The use: cancer that has spread to bone. The upshot: an approval could boost sales of the new drug to roughly $3 billion by 2015, analysts say.

Prolia won the FDA nod as an osteoporosis treatment June 1. But the drug isn’t expected to vault to quick success in that market. After all, it’s crowded with alternatives such as Merck’s Fosamax, which recently went generic, and Roche’s Boniva. Recently, Decision Resources predicted that the drug could build to just $500 million in osteoporosis sales by 2019.

Amgen is really counting on pushing Prolia as a treatment for cancer patients. That’s why it submitted data for this second indication even before it won FDA’s initial approval. The sooner it can get a cancer approval, the sooner it can start touting Prolia to a very receptive market. With this priority-review designation, that date could be as soon as November 18.

- get the release from Amgen
- read the PharmaTimes story

-More here.

Novelos revives failed lung cancer drug

Wednesday, July 14th, 2010

After suffering a serious setback when NOV-002 flunked a late-stage clinical trial for lung cancer earlier this year, Novelos says the same drug proved effective in combination with chemotherapy during a small Phase II trial for breast cancer. But the news failed to inspire much hope among disillusioned investors. Its shares (NVLT) were trading at 14 cents this morning.

“We are excited about this proof of concept trial and we are excited to have NOV-002 back in the game,” Novelos CEO Harry Palmin said yesterday. The breast cancer trial enrolled 39 patients and tested if the preoperative use of NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel could at least double the complete response rate. Palmin added that the company would discuss the outlines of a bigger placebo trial with the FDA.

Back in February shares of Novelos were hit hard after the Newton, MA-based Novelos announced that NOV-002 had failed a late-stage trial for lung cancer. The biotech company shelved that program a month later.

- check out the Novelos release
- here’s the story from the Boston Business Journal and John Carroll

New Research Model of Human Prostate Cancer Shows Cancer Development

Friday, July 9th, 2010

New Research Model of Human Prostate Cancer Shows Cancer Development

ScienceDaily (July 1, 2010) – Progress toward understanding the role of sex hormones in the growth of prostate cancer — the most common cancer in U.S. men — has been hindered by the lack of a suitable laboratory research model. Now researchers say they have developed the first model of hormone-induced human prostate cancer initiation and progression.

Their results were presented at The Endocrine Society’s 92nd Annual Meeting in San Diego.

“We hope this model will speed up the process of testing preventive therapies for prostate cancer as well as help clarify the hormonal mechanisms in the development of this cancer,” said Gail Prins, PhD, a professor and reproductive physiologist at the University of Illinois at Chicago, who is a co-author of the study.

“Sex hormones — testosterone and estrogens — are involved in regulating the growth of prostate cancer, but the mechanisms are not well established,” Prins said.

Currently the only available laboratory models of human prostate cancer are xenografts — cancerous human tissues grafted under the skin of animals — or “transformed” cancer cell lines containing cells that originally came from patients with prostate cancer. However, Prins said, “If you want to study the initial development of cancer — either naturally or induced — or its prevention, you cannot use a model of existing cancer, such as transformed cell lines.”

To study the progression of prostate cancer from normal cells into cancerous cells requires the use of animal prostate cells. Animal models, however, do not directly mimic all aspects of human prostate cancer, experts say.

Prins and her colleagues created their model using prostate cells obtained from a deceased organ donor who did not have prostate disease. They isolated and grew, in 3-D culture, adult prostate progenitor cells — cells with stem cell-like properties that self-renew and may become cancerous. In 3-D culture, the progenitor cells proliferate and form small spheroids, called prostaspheres, which are capable of regenerating tissues.

The researchers combined these human prostaspheres with embryonic cells from the prostate of a rat and then transplanted the mixed cells under the kidney capsule of mice. These transplants regenerated into normal human prostate-like tissues and secreted prostate-specific antigen (PSA), which confirmed human functionality, according to Prins.

The mice then received a drug pellet containing testosterone and estradiol estrogen. A cancerous tumor formed at the transplant site.

“We were able to induce hormonally driven prostate cancer in these recombinant tissues,” Prins said. “Using this model, we can follow the entire pathway of the cancer — from normal tissue to initiation and progression.”

Read more here.

Blood cells can generate stem cells, studies show

Thursday, July 8th, 2010

Researchers have successfully reprogrammed human blood cells into embryonic-like stem cells according to three news studies. Experts say this has the potential for changing the course of stem cell research.

Three years ago, researchers in Japan and the United States announced they had taken a simple skin cell – inserted four viruses, which reprogrammed the blood cells to an embryonic stem-cell like state and a source of embryonic-like stems cells. These cells are called induced pluripotent stem cells (IPS cells) and are believed to have the ability to turn into any cell in the body, just like embryonic stem cells, but without the controversy of destroying an embryo, which happens when embryonic stem cells are removed from the embryo.

This week, three groups of researchers report having generated IPS cells from blood. The studies were published Thursday in the journal Cell Stem Cell.

The benefit of using IPS cells is that eventually, doctors could take a patient’s skin cells and make IPS cells from it and any therapies made from these cells wouldn’t be rejected because they have the same DNA as the patient. But first the patient has to undergo a skin biopsy for scientists to get the skin cell, which can be cumbersome, costly and sometimes cause some side effects.

However, drawing blood is much easier than taking a skin biopsy. Researchers in Japan used as little as 1 ml of blood (=0.03 ounces). Plus, researchers can take advantage of already drawn blood. Scientists from the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, used frozen blood. This opens up more research possibilities because scientists could use blood stored in tissue banks and study the diseases of people who may have moved away or passed on.

The goal of IPS cell research is to “transfer the disease into the test tube” says Dr. Rudolph Jaenisch, a founding member of the Whitehead Institute and stem expert. He says it wasn’t easy making IPS cells from blood, but having the ability to do so now will allow researchers to have easy access to a widely available source for generating IPS cells. These IPS cells will have all the genetic alterations that have contributed to the illness of a patient. Jaenisch says researchers can now grow nerve cells or other cells that are affected by a disease like Parkinson’s and study the progression of disease.

Dr. John Gearhart, who heads the University of Pennsylvania’s Institute of Regenerative Medicine , says these three papers “are quite important to the IPS field.”  He says being able to make IPS cells from blood will be much more practical for patients and researchers.

Dr. Shinya Yamanaka led one of the two teams that made the first human IPS cells from skin cells. He writes in an accompanying article for the journal, that the three studies “represent a huge and important progression in the field.”

Here is the full story.

Cancer Stem Cells Are Not ‘One Size Fits All,’ Lung Cancer Models Show

Wednesday, July 7th, 2010

Cancer stem cells have enticed scientists because of the potential to provide more durable and widespread cancer cures by identifying and targeting the tumor’s most voracious cells. Now, researchers at Children’s Hospital Boston and their colleagues have identified cancer stem cells in a model of the most common form of human lung cancer and, more significantly, have found that the cancer stem cells may vary from tumor to tumor, depending upon the tumor’s genetic signature.

“Our study shows the cancer stem cell hypothesis is true in some lung cancers,” said senior author Carla Kim, PhD, an assistant professor in the Stem Cell Program at Children’s Hospital Boston and the department of genetics at Harvard Medical School (HMS). “It also shows, from one lung cancer to another, the cancer stem cells are not the same.”

Cancer stem cells are a subset of cancer cells believed to elude conventional treatments and eventually regenerate a tumor. Experimentally, they show up as cells that can be extracted from a tumor and transplanted to form a new tumor, from which the same tumor-propagating cells can again be extracted and transplanted with the same result. According to Kim, this is the first serial transplantation study to identify lung cancer tumor-propagating cells….

Find the full story here.

Frozen blood a source of stem cells, study finds

Friday, July 2nd, 2010

(Reuters) – Frozen blood from stored samples can be used to make cells resembling stem cells, researchers said on Thursday — opening a potential new and easier source for the valued cells.

They used cells from blood to make induced pluripotent stem cells or iPS cells — lab-made cells that closely resemble human embryonic stem cells but are made from ordinary tissue.

These iPS cells have in the past been made from plugs of skin, but blood is much easier to take from people and to store, the researchers reported in the journal Cell Stem Cell.

“Blood is the easiest, most accessible source of cells, because you’d rather have 20 milliliters of blood drawn than have a punch biopsy taken to get skin cells,” Judith Staerk of the Whitehead Institute for Biomedical Research in Massachusetts, who worked on the study, said in a statement.

Stem cells are the body’s master cells, the source of renewed blood and tissue. So-called adult stem cells exist through life but they are partially developed.

Embryonic stem cells from days-old embryos have the ability to become all the cell types in the body and also can proliferate in the lab for years.

IPS cells are made by activating three or four genes that distinguish embryonic stem cells.

Whitehead’s Rudolf Jaenisch, who directed the work, said being able to use blood will open opportunities for researchers who want to use iPS cells to study how diseases develop.

“There are enormous resources — blood banks with samples from patients that may hold the only viable cells from patients who may not be alive any more, or from the early stage of their diseases,” Jaenisch said.

“Using this method, we can now resurrect those cells as induced pluripotent stem cells. If the patient had a neurodegenerative disease, you can use the iPS cells to study that disease.”

(Reporting by Maggie Fox; Editing by Julie Steenhuysen)

miRNA’s prevalence in Oncology/Hematology | Conversant

Friday, June 25th, 2010

Over the past few years, miRNA have become a very hot topic in the fields of Oncology and Hematology. After these post-transcriptional regulators were discovered in the late 1990′s and classified as a distinct set of biological regulators in the early 2000′s, much more has been discovered about their regulation in the body. Since they have been heavily studied, negative effects of  miRNA have been identified, among these are: transcript degradation and sequestering and translational suppression.

A few recent studies have shown links between miRNA and the development of cancer.  Because these miRNA play an important role cell differentiation, proliferation, apoptosis, and chromosome structure, there is significant reason to believe they play a role in the cancer biology.

The link to cancer and other disorders such as heart disease and nervous system disorders is one reason why miRNA’s have become such a hot topic at recent ASH and AACR meetings. Several studies are currently underway to further understand the role of miRNA and how they could possible act as oncogenes.

As always, if you have further questions or inquiries, please feel free to fill out a request form and someone will get back with you shortly, use our on-line chat or contact us at (866)-838-2798.